The guidance included collective net revenue contribution from Optune Lua and Optune Pax between $20 million and $30 million. It also expects to turn into a positive adjusted EBITDA of up to $15 million, reversing an adjusted EBITDA loss outlook of $15 million previously. Revenues Up 16%The higher outlook was encouraged by its strong results in the second quarter of the year. “This was our strongest quarter to date, with record net revenues and active patients on therapy,” CEO Frank Leonard said. READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.